Jessica J Lin1, Viola W Zhu2, Adam J Schoenfeld3, Beow Y Yeap1, Ashish Saxena4, Lorin A Ferris1, Ibiayi Dagogo-Jack1, Anna F Farago1, Angela Taber5, Anne Traynor6, Smitha Menon7, Justin F Gainor1, Jochen K Lennerz8, Andrew J Plodkowski9, Subba R Digumarthy10, Sai-Hong Ignatius Ou2, Alice T Shaw11, Gregory J Riely3. 1. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 2. Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medicine, Weill Cornell Medicine, New York, New York. 5. Lifespan Cancer Institute, Providence, Rhode Island. 6. Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin. 7. Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. 8. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. 9. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 10. Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts. 11. Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: ashaw1@partners.org.
Abstract
INTRODUCTION: The second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced ALK-rearranged NSCLC, establishing alectinib as the new standard first-line therapy. Brigatinib, another second-generation ALK inhibitor, has shown substantial activity in patients with crizotinib-refractory ALK-positive NSCLC; however, its activity in the alectinib-refractory setting is unknown. METHODS: A multicenter, retrospective study was performed at three institutions. Patients were eligible if they had advanced, alectinib-refractory ALK-positive NSCLC and were treated with brigatinib. Medical records were reviewed to determine clinical outcomes. RESULTS: Twenty-two patients were eligible for this study. Confirmed objective responses to brigatinib were observed in 3 of 18 patients (17%) with measurable disease. Nine patients (50%) had stable disease on brigatinib. The median progression-free survival was 4.4 months (95% confidence interval [CI]: 1.8-5.6 months) with a median duration of treatment of 5.7 months (95% CI: 1.8-6.2 months). Among 9 patients in this study who underwent post-alectinib/pre-brigatinib biopsies, 5 had an ALK I1171X or V1180L resistance mutation; of these, 1 had a confirmed partial response and 3 had stable disease on brigatinib. One patient had an ALK G1202R mutation in a post-alectinib/pre-brigatinib biopsy, and had progressive disease as the best overall response to brigatinib. CONCLUSIONS: Brigatinib has limited clinical activity in alectinib-refractory ALK-positive NSCLC. Additional studies are needed to establish biomarkers of response to brigatinib and to identify effective therapeutic options for alectinib-resistant ALK-positive NSCLC patients.
INTRODUCTION: The second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced ALK-rearranged NSCLC, establishing alectinib as the new standard first-line therapy. Brigatinib, another second-generation ALK inhibitor, has shown substantial activity in patients with crizotinib-refractory ALK-positive NSCLC; however, its activity in the alectinib-refractory setting is unknown. METHODS: A multicenter, retrospective study was performed at three institutions. Patients were eligible if they had advanced, alectinib-refractory ALK-positive NSCLC and were treated with brigatinib. Medical records were reviewed to determine clinical outcomes. RESULTS: Twenty-two patients were eligible for this study. Confirmed objective responses to brigatinib were observed in 3 of 18 patients (17%) with measurable disease. Nine patients (50%) had stable disease on brigatinib. The median progression-free survival was 4.4 months (95% confidence interval [CI]: 1.8-5.6 months) with a median duration of treatment of 5.7 months (95% CI: 1.8-6.2 months). Among 9 patients in this study who underwent post-alectinib/pre-brigatinib biopsies, 5 had an ALKI1171X or V1180L resistance mutation; of these, 1 had a confirmed partial response and 3 had stable disease on brigatinib. One patient had an ALKG1202R mutation in a post-alectinib/pre-brigatinib biopsy, and had progressive disease as the best overall response to brigatinib. CONCLUSIONS:Brigatinib has limited clinical activity in alectinib-refractory ALK-positive NSCLC. Additional studies are needed to establish biomarkers of response to brigatinib and to identify effective therapeutic options for alectinib-resistant ALK-positive NSCLCpatients.
Authors: Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw Journal: Cancer Discov Date: 2016-07-18 Impact factor: 39.397
Authors: Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman Journal: N Engl J Med Date: 2014-03-27 Impact factor: 91.245
Authors: Dong-Wan Kim; Marcello Tiseo; Myung-Ju Ahn; Karen L Reckamp; Karin Holmskov Hansen; Sang-We Kim; Rudolf M Huber; Howard L West; Harry J M Groen; Maximilian J Hochmair; Natasha B Leighl; Scott N Gettinger; Corey J Langer; Luis G Paz-Ares Rodríguez; Egbert F Smit; Edward S Kim; William Reichmann; Frank G Haluska; David Kerstein; D Ross Camidge Journal: J Clin Oncol Date: 2017-05-05 Impact factor: 44.544
Authors: Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; Rebecca S Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate Journal: J Clin Oncol Date: 2009-08-10 Impact factor: 44.544
Authors: Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok Journal: N Engl J Med Date: 2017-06-06 Impact factor: 91.245
Authors: Sen Zhang; Rana Anjum; Rachel Squillace; Sara Nadworny; Tianjun Zhou; Jeff Keats; Yaoyu Ning; Scott D Wardwell; David Miller; Youngchul Song; Lindsey Eichinger; Lauren Moran; Wei-Sheng Huang; Shuangying Liu; Dong Zou; Yihan Wang; Qurish Mohemmad; Hyun Gyung Jang; Emily Ye; Narayana Narasimhan; Frank Wang; Juan Miret; Xiaotian Zhu; Tim Clackson; David Dalgarno; William C Shakespeare; Victor M Rivera Journal: Clin Cancer Res Date: 2016-10-25 Impact factor: 12.531
Authors: S Novello; J Mazières; I-J Oh; J de Castro; M R Migliorino; Å Helland; R Dziadziuszko; F Griesinger; A Kotb; A Zeaiter; A Cardona; B Balas; H K Johannsdottir; A Das-Gupta; J Wolf Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw Journal: Lancet Oncol Date: 2016-03-11 Impact factor: 41.316
Authors: Raymond U Osarogiagbon; Diana Merino Vega; Lola Fashoyin-Aje; Suparna Wedam; Gwynn Ison; Sol Atienza; Peter De Porre; Tithi Biswas; Jamie N Holloway; David S Hong; Madison M Wempe; Richard L Schilsky; Edward S Kim; James L Wade Journal: Clin Cancer Res Date: 2021-02-09 Impact factor: 12.531